Entropy Neurodynamics (ASX:ENP) was granted an Australian patent covering its two-phase dosing method of administering psychedelic drug psilocybin, psilocin, and related forms to treat a range of psychological and nociplastic pain disorders, according to a Thursday Australian bourse filing.

The proprietary dosing method covered by the patent, which will run through to 2042, includes a loading dose followed by a controlled maintenance infusion, the filing said.

The patent protects elements, such as the rapid induction of the psychedelic state or therapeutic window, within a defined period of five to 30 minutes and controlled maintenance of drug levels over the treatment period.

The company's shares rose nearly 7% in recent trading on Thursday.